We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Initial Therapy for Diabetes Mellitus

Jodi B. Segal, MD, MPH1; Nisa M. Maruthur, MD, MHS1
[+] Author Affiliations
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA Intern Med. 2014;174(12):1962-1963. doi:10.1001/jamainternmed.2014.4296.
Text Size: A A A
Published online


Berkowitz and colleagues1 assert that there is little comparative effectiveness evidence to guide initial selection of therapy for diabetes mellitus. They therefore conducted this rigorous study to determine effects attributable to initial oral glucose-lowering agents. With a retrospective cohort design using 4 years of recent claims data from a large national insurer, they investigated outcomes from 4 classes of oral diabetes medications (metformin, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase 4 inhibitors). In their adjusted models, initiation of therapy with a sulfonylurea, thiazolidinedione, or dipeptidyl phosphatase 4 inhibitor was associated with an increased hazard of treatment intensification (addition of another drug) relative to first therapy with metformin, without greater clinical benefits (and often more short-term adverse events). The authors noted that only 57.8% of individuals in their data set began pharmaceutical management of their diabetes with metformin. This study understandably omitted the newest class of medications—the sodium-dependent glucose transporter 2 inhibitors—because the first drug was not approved in the United States until March 2013. Less understandable is the exclusion of injectable medications from the glucagon-like peptide 1 agonist class despite their approval for use as monotherapy and availability since 2005.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Diabetes, Foot Ulcer

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Diabetic Peripheral Neuropathy